SciBase Strengthens Partnership with Castle Biosciences Through New Order

SciBase Enhances Collaboration with Castle Biosciences

Stockholm, Sept. 8, 2026 – SciBase Holding AB, recognized as a leader in AI technology for dermatology, has announced an additional order bolstering its ongoing partnership with Castle Biosciences. This order represents a significant step in both accelerating a current clinical study and paving the way for a forthcoming second study. The latest agreement includes the procurement of the portable Nevisense Go devices along with necessary electrodes, valued at around $0.6 million or nearly 5 million Swedish Krona (MSEK).

In 2025, SciBase embarked on an exciting journey by collaborating with Castle Biosciences, a prominent player in the field of molecular diagnostics based in the United States. This partnership is focused on predicting relapses in atopic dermatitis, a prevalent condition affecting skin health. The current clinical study is already in motion, and the newly placed order is intended not only to expedite this initial study but also to set the groundwork for an additional clinical trial, with delivery expected to commence in the fourth quarter of 2026.

Pia Renaudin, CEO of SciBase, expressed enthusiasm regarding the progression of this collaboration, stating, "The partnership with Castle Biosciences is advancing rapidly, characterized by swift patient recruitment in our initial study. This new order signifies our ongoing commitment to expand our collaborative efforts."

Renaudin highlighted SciBase’s mission to enhance patient care by improving accessibility to effective treatments for skin barrier disorders. The technology behind the Nevisense device integrates artificial intelligence with advanced electrical impedance spectroscopy (EIS), a method that augments diagnostic accuracy and supports proactive skin health management.

With over 20 years of dedicated research and development originating from the Karolinska Institute in Stockholm, SciBase remains at the forefront of dermatological innovation. The company's primary goal is to alleviate patient suffering, enabling healthcare providers to enhance lives through timely detection and intervention, while also working toward a reduction in healthcare costs.

The Nevisense system allows for point-of-care evaluations that are crucial in dermatology, particularly for conditions such as atopic dermatitis. As patient needs continue to grow, SciBase is committed to advancing its technologies and partnerships, ensuring they meet the challenges faced in modern healthcare.

SciBase’s stock is currently listed on the Nasdaq First North Growth Market, having been publicly traded since June 2, 2015. The company's certified adviser is Carnegie Investment Bank AB (publ). For more detailed information about SciBase's initiatives and future plans, visit www.scibase.com or their investor portal for financial releases at investors.scibase.se.

In summary, the collaboration between SciBase and Castle Biosciences marks a significant leap towards better treatment options for patients suffering from atopic dermatitis. With a focus on innovative technology and research, the future looks promising for those seeking advanced dermatological care.